Hybridan Small Cap Feast - 15 April 24

15th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated propositio

Hybridan Small Cap Feast - 27 Feb 24

27th February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj

Allenby Capital: Fusion Antibodies - Update

Fusion has conditionally raised c. £1.4m (gross) by way of a placing of 34.4m shares at 4p per share. The financing provides a cash runway to mid CY2025 and comes as the hoped-for turnaround in trading is becoming more apparent, notably with the recent award of a $650k follow-on project. The cash reach now extends into Fusion’s FY26, beyond the point where it aims to be trading on a cash neutral basis. Fusion reports visibility of £1.15m in revenue in FY24 and, although the company could close a

Hybridan Small Cap Feast - 14 Feb 24

14th February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj

Allenby Capital: Fusion Antibodies - Interims

After a very tough first half of FY24, Fusion appears to be seeing some signs of the hoped-for turnaround in trading, helped by its decision to broaden its client base from biopharma into the adjacent sectors of veterinary drugs and diagnostics. This has been seen in the form of rising month on month revenue that allowed it to be broadly cash neutral in October. However, given its cash reach that extends into FY25, an upturn in the second half is crucial to the investment case. Recently reported

Hybridan Small Cap Feast - 28/11/2023

28th November 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj

Allenby Capital: Fusion Antibodies - Update

Fusion Antibodies plc (FAB.L), the provider of services for pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has warned that its FY24 H1 revenue is c. 23% below expectations at no less than £541k (vs £700k forecast). This reflects the weak trading environment and certain one-off delays associated with some contracts. Given that the investment case depends on a turnaround in trading – which is only just starting to materialise - we hav

Allenby Capital: Fusion Antibodies - Finals

Fusion’s FY23 results were in line with revised expectations but are more important as an opportunity to highlight progress of its turnaround strategy. A restructuring, conducted after the May fundraising, is now complete giving Fusion a minimum 15- month cash runway at its reduced cost base. Although no material new contracts have been disclosed since May, we understand Q1 FY24 revenue was in line with internal expectations and Fusion has executed the first of what it hopes will be a number of

Hybridan Small Cap Feast 14/08/23

Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Announced ITF 4 August: Tan Delta Systems plc, a Sheffield based Company intends to IPO on AIM. Tan Delta has developed an innovative and differentiated monitoring solution based on real time oil analysis and analytics that offers equipment operators enhanced insight into the maintenance status of their equipment and thus the ability to reduce maintenance costs, improve reliability and reduce carbon footpr

Fusion Antibodies Update

Fusion Antibodies has announced a £1.5m fundraising concurrently with a cost cutting exercise that should together provide it with an 18-month cash runway as it transitions towards a higher-value proposition. The fundraising is being conducted at 5p/share, a price that reflects the current adverse funding environment. A new strategy will see the focus shift towards commercialising the new integrated service offering and exploiting AI partnership opportunities, ahead of OptiMAL and OptiPhage. We

Hybridan Small Cap Feast - 19 May 23

19th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Hybridan Small Cap Feast - 21 Mar 23

21 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Fusion Antibodies Update

Delays in closing larger integrated service contract(s) currently under discussion and continued weakness in its traditional smaller contract base have caused Fusion to issue a trading statement warning that its FY23 revenues are likely to be materially below market expectations. This has had a predictable impact on the share price, down c. 25% yesterday, despite there being a good chance that a large contract will still be awarded in the near term, albeit with revenue falling into FY24. We have

Fusion Antibodies Update

The roll out of the new OptiMal platform is underway. This is being done in stages as modules are tested and validated. The initial commercialisation module generates a variety of human antibodies on the surfaces of mammalian cells. These can be screened to select the best ones for further development. This innovation is expected to be very valuable especially to AI-based drug developers who need to test their algorithmic creations in the real world. We anticipate further OptiMAL stages becomi

Warpaint London+ (W7L, House Stock at 375p) - Trading ahead of expectations - +10% upgrade implied

The Hardman & Co Monthly: April 2024

Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol

Morning Note – 9 April 2024

Morning Note – 8 April 2024

Avon Protection - Unmasking its growth potential

Avon Protection’s capital markets day highlighted its continued focus on medium-term margin expansion (targeting operating margin of 14–16%), concentrating on its core business of respirators and head protection. The unwinding of the armour business, alongside the consolidation of Team Wendy (acquired in H220) should enable Avon to benefit from rising global defence spending. Its strong relationship with the US DoD, and organic growth opportunities with recurring revenue from necessary product r

Cambridge Nutritional Sciences - H1 2024 interims: Executing a newly focussed st

Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We

Venture Life Group - Strong organic growth; focus on EBITDA

Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli

Hybridan Small Cap Feast - 17 April 24

17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi

Morning Note – 22 March 2024

LIBERUM: Futura Medical: An increasing degree of confidence

The Hardman & Co Monthly: March 2024

Feature article: Streamed content takes over…after the Great Correction of 2022 Streaming is a disruptive, content-led, subscription-based technology. Challenging all video distribution business models, it opens up global opportunities for a growing variety of content, including gaming and sport. The Great Correction of 2022 saw the share prices of streamers plunge after market leader Netflix reported slowing subscriber growth. The slowdown in growth of subscribers led investors to refocus on

Diaceutics | FY23 update – 22% revenue growth, £16.7m YE cash

Diaceutics has released a trading statement for the year to December 2023 guiding to revenue growth of 22% YoY to £23.7m, up 19% on a constant currency basis. The order book jumped 57% to £26.6m, of which c£12.3m is expected to be realised in FY24, and which currently stands at £30.8m. The proportion of recurring revenue continues to increase and is now over 50% (FY22 35%). Cash at YE23 stood at £16.7m, indicating a near halving of the rate of cash burn in 2H23 compared to 1H23. We adjust our FY

Belluscura Trading Update

Belluscura has released a Trading Update stating that due to the delay in securing funding and Chinese NMPA approval, sales and manufacturing have been delayed by at least four months and it now expects EBITDA breakeven in Q3 and to turn cashflow positive in Q1 2025.

Zoetis Inc.: Launch Of CircoMatch & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (02/23)

Zoetis delivered a decent set of results for the last quarter of 2022 meeting analyst expectations as well as the high end of its management guidance. Despite the economic challenges, ongoing pandemic recovery, and the political unpredictability brought on by the war in Ukraine, they delivered operational growth for the year in each of their top 13 markets. The company's unique companion animal portfolio drove its 8% operational revenue increase for the year, growing 14% operationally. In compar

Morning Note – 12 February 2024